• $460.0M
    Market Cap
  • 145.56%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
0
N/A
0
-100.00%
429,039
+1,082.64%
36,278
+51.01%
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
-100.00%
429,039
+1,082.64%
36,278
+51.01%
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-9.9M
-23.85%
-13.0M
+132.24%
-5.6M
-26.23%
-7.6M
+16.92%
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
16.7M
+3.36%
16.2M
+83.01%
8.8M
-16.19%
10.5M
+15.44%
Operating Profit
-16.7M
+3.36%
-16.2M
+83.01%
-8.8M
-16.19%
-10.5M
+15.44%
Interest Income
3.0M
+639.45%
404,020
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
3.0M
+639.45%
404,020
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
0
-100.00%
171,282
-60.08%
429,039
+1,920.05%
21,239
-11.59%
Income before Taxes
-16.7M
+3.36%
-16.2M
+83.01%
-8.8M
-16.19%
-10.5M
+15.44%
Income Taxes
800
0.00%
800
0.00%
800
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-13.7M
-11.99%
-15.6M
+85.50%
-8.4M
-20.10%
-10.5M
+15.52%
Net Income from Continuing Operations Applicable to Common
-13.7M
-11.99%
-15.6M
+85.50%
-8.4M
-20.10%
-10.5M
+15.52%
Basic EPS and Net Income
-1.85
-54.99%
-4.11
+573.77%
-0.61
N/A
N/A
N/A
Diluted EPS and Net Income
-1.85
-54.99%
-4.11
+573.77%
-0.61
N/A
N/A
N/A
Basic Weighted Average Shares
7.4M
+95.53%
3.8M
-72.58%
13.8M
+8.69%
12.7M
+1.97%
Diluted Weighted Average Shares
7.4M
+95.53%
3.8M
-72.58%
13.8M
+8.69%
12.7M
+1.97%
Balance Sheet
Cash and Cash Equivalents
61.8M
+34.96%
45.8M
+530.55%
7.3M
-11.24%
8.2M
-59.68%
Short-Term Investments
12.8M
-68.91%
41.0M
+526.86%
6.5M
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
74.6M
-14.11%
86.8M
+528.80%
13.8M
+68.71%
8.2M
-59.68%
Total Current Assets
140.5M
+132.97%
60.3M
+722.24%
7.3M
-44.31%
13.2M
-35.84%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Assets
140.7M
+133.40%
60.3M
+720.83%
7.3M
-44.47%
13.2M
-35.55%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
2.7M
+21.33%
2.3M
+28.28%
1.8M
-43.83%
3.1M
+97.96%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
154,920
N/A
N/A
N/A
0
-100.00%
8,408
N/A
Total Liabilities
2.9M
-44.99%
5.3M
+198.98%
1.8M
-43.98%
3.1M
+98.50%
Retained Earnings
-89.5M
+18.10%
-75.8M
+25.89%
-60.2M
+16.22%
-51.8M
+25.47%
Total Stockholders Equity
137.8M
+150.43%
55.0M
+884.95%
5.6M
-44.62%
10.1M
-46.73%
Total Shares Outstanding
6.7M
+9.66%
6.1M
-59.06%
14.9M
+15.12%
12.9M
+2.77%
Cash Flow
Cash from Operating Activities
-12.2M
+90.52%
-6.4M
-18.50%
-7.9M
+8.71%
-7.2M
-198.79%
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
-63.5M
+342.54%
-14.3M
-390.97%
4.9M
+200.19%
-4.9M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
91.6M
+54.45%
59.3M
+2,824.80%
2.0M
+6,066.85%
32,873
-99.70%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
-2,058.38%
-92.91%
-29,044.81%
-23.55%
Return on Assets
-13.65%
-70.39%
-46.09%
-43.58%
-81.69%
+31.08%
-62.32%
+27.98%
Return on Equity
-14.22%
-72.34%
-51.42%
-52.03%
-107.19%
+47.96%
-72.44%
+37.81%
Revenue Growth
N/A
N/A
-100.00%
-109.24%
1,082.64%
+2,022.52%
51.01%
+172.18%
Current Ratio
51.35
+92.01%
26.74
+541.00%
4.17
-0.84%
4.21
-67.59%
Cash Ratio
22.61
+11.23%
20.32
+391.56%
4.13
+58.03%
2.62
-79.63%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow